Healome Therapeutics clôture une levée de fonds d'amorçage de 2 millions de livres sterling menée par Empirical Ventures afin de faire progresser sa technologie de matrice de collyre destinée au traitement des maladies de la surface oculaire

Healome Therapeutics, a University of Birmingham spin-out developing an exclusive corneal-surface delivery technology, has closed a funding round (amount not provided in the available text). The update is directionally positive for the company’s financing position, but details are insufficient here to assess broader market impact.

Analysis

Healome Therapeutics, a University of Birmingham spin-out developing an exclusive corneal-surface delivery technology, has closed a funding round (amount not provided in the available text). The update is directionally positive for the company’s financing position, but details are insufficient here to assess broader market impact.